JP2022515770A5 - - Google Patents

Info

Publication number
JP2022515770A5
JP2022515770A5 JP2021535950A JP2021535950A JP2022515770A5 JP 2022515770 A5 JP2022515770 A5 JP 2022515770A5 JP 2021535950 A JP2021535950 A JP 2021535950A JP 2021535950 A JP2021535950 A JP 2021535950A JP 2022515770 A5 JP2022515770 A5 JP 2022515770A5
Authority
JP
Japan
Prior art keywords
bispecific antibody
heavy chain
domain
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021535950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515770A (ja
JP7530362B2 (ja
Filing date
Publication date
Priority claimed from GBGB1820977.5A external-priority patent/GB201820977D0/en
Priority claimed from GBGB1906816.2A external-priority patent/GB201906816D0/en
Priority claimed from GBGB1908190.0A external-priority patent/GB201908190D0/en
Application filed filed Critical
Priority claimed from PCT/EP2019/086808 external-priority patent/WO2020128049A1/en
Publication of JP2022515770A publication Critical patent/JP2022515770A/ja
Publication of JP2022515770A5 publication Critical patent/JP2022515770A5/ja
Application granted granted Critical
Publication of JP7530362B2 publication Critical patent/JP7530362B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535950A 2018-12-21 2019-12-20 共通の軽鎖を有するFIXa×FX二重特異性抗体 Active JP7530362B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1820977.5 2018-12-21
GBGB1820977.5A GB201820977D0 (en) 2018-12-21 2018-12-21 Fixaxfx bispecific antibody with commomn light chain
GB1906816.2 2019-05-15
GBGB1906816.2A GB201906816D0 (en) 2019-05-15 2019-05-15 FIXaxFX bispecific antibody with common light chain
GB1908190.0 2019-06-07
GBGB1908190.0A GB201908190D0 (en) 2019-06-07 2019-06-07 Fixaxfx bispecific antibody with common light chain
PCT/EP2019/086808 WO2020128049A1 (en) 2018-12-21 2019-12-20 Fixaxfx bispecific antibody with common light chain

Publications (3)

Publication Number Publication Date
JP2022515770A JP2022515770A (ja) 2022-02-22
JP2022515770A5 true JP2022515770A5 (cg-RX-API-DMAC7.html) 2022-12-28
JP7530362B2 JP7530362B2 (ja) 2024-08-07

Family

ID=69167786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535950A Active JP7530362B2 (ja) 2018-12-21 2019-12-20 共通の軽鎖を有するFIXa×FX二重特異性抗体

Country Status (18)

Country Link
US (3) US20220064327A1 (cg-RX-API-DMAC7.html)
EP (2) EP4015538A1 (cg-RX-API-DMAC7.html)
JP (1) JP7530362B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210118085A (cg-RX-API-DMAC7.html)
CN (1) CN113453757B (cg-RX-API-DMAC7.html)
BR (1) BR112021012065A2 (cg-RX-API-DMAC7.html)
CA (1) CA3123177A1 (cg-RX-API-DMAC7.html)
DK (1) DK3723858T3 (cg-RX-API-DMAC7.html)
ES (1) ES2901683T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220088T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057634T2 (cg-RX-API-DMAC7.html)
LT (1) LT3723858T (cg-RX-API-DMAC7.html)
PL (1) PL3723858T3 (cg-RX-API-DMAC7.html)
PT (1) PT3723858T (cg-RX-API-DMAC7.html)
RS (1) RS62848B1 (cg-RX-API-DMAC7.html)
SI (1) SI3723858T1 (cg-RX-API-DMAC7.html)
TW (1) TWI772724B (cg-RX-API-DMAC7.html)
WO (1) WO2020128049A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
TWI772724B (zh) 2018-12-21 2022-08-01 英商克馬伯有限公司 具有共同輕鏈的FIXaxFX雙專一性抗體
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies
WO2020229621A1 (en) * 2019-05-15 2020-11-19 Kymab Limited Improved lambda antibodies
CN115728433B (zh) * 2021-08-27 2024-11-15 联邦生物科技(珠海横琴)有限公司 IgG4型单克隆抗体电荷异质性的离子交换色谱检测方法
WO2023111018A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Antibodies against coagulation factor x and uses thereof
WO2023147574A2 (en) * 2022-01-31 2023-08-03 The Children's Hospital Of Philadelphia Compositions and methods for treating factor ix deficiency
US12098400B2 (en) 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
GB202319967D0 (en) 2023-12-22 2024-02-07 Epsilogen Ltd Heteromultimeric proteins
WO2026036047A1 (en) * 2024-08-08 2026-02-12 Altus Enterprises, Inc. Antibody molecules to fixa and fx and uses thereof
WO2026037918A1 (en) 2024-08-14 2026-02-19 Epsilogen Ltd Heteromultimeric proteins

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP2824183B1 (en) 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing bispecific antibodies
CA2614076A1 (en) 2005-07-05 2007-01-11 Glaxo Group Limited Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
CA2650131A1 (en) * 2006-04-14 2007-10-25 Amgen Inc. Agonist erythropoietin receptor antibodies
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
AU2010336277B2 (en) * 2009-12-25 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Polypeptide modification method for purifying polypeptide multimers
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US20140356377A1 (en) 2011-08-25 2014-12-04 Umc Utrecht Holding B.V. Compounds for use in boosting coagulation
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CN104854133B (zh) 2012-10-12 2018-10-30 新加坡科技研究局 用于制备重组抗体治疗剂的最佳重链和轻链信号肽
CA2904805A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
EP3065768B1 (en) 2013-11-04 2020-09-23 The Regents of the University of California Composition for use in treatment or prevention of conditions associated with bleeding or hypocoagulationcompostion
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
TW201625299A (zh) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
CA2978038A1 (en) 2015-04-17 2016-10-20 F. Hoffmann-La Roche Ag Combination therapy with coagulation factors and multispecific antibodies
JP2018123055A (ja) 2015-04-24 2018-08-09 公立大学法人奈良県立医科大学 血液凝固第viii因子(fviii)の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第xi因子(fxi)異常症の予防および/または治療に用いられる医薬組成物
WO2016207402A1 (en) * 2015-06-26 2016-12-29 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
JP6920293B2 (ja) 2015-10-30 2021-08-18 メドイミューン・リミテッドMedImmune Limited IgG軽鎖におけるN末端切断の防止
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
WO2017132827A1 (en) * 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
JP7014724B2 (ja) 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Fab免疫グロブリンおよびその使用
SG11201809642TA (en) 2016-05-16 2018-11-29 Baxalta Inc Anti-factor ix padua antibodies
CA3027018A1 (en) * 2016-07-29 2018-02-01 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
US11352438B2 (en) 2016-09-06 2022-06-07 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
AU2017363309A1 (en) * 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
AU2018216008A1 (en) 2017-02-01 2019-08-01 Novo Nordisk A/S Procoagulant antibodies
WO2018145125A1 (en) 2017-02-06 2018-08-09 Applied Stemcell, Inc. Coagulation factor viii mimetic protein and uses thereof
EP3615574B1 (en) * 2017-04-26 2026-06-24 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
WO2018209265A1 (en) 2017-05-11 2018-11-15 Atreca, Inc. Anti-malarial antibodies that bind circumsporozoite protein
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CA3071236A1 (en) 2017-09-29 2019-04-04 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient
CN111386285B (zh) 2017-11-15 2024-08-27 诺和诺德股份有限公司 增强fx活化的因子x结合物
TWI772724B (zh) * 2018-12-21 2022-08-01 英商克馬伯有限公司 具有共同輕鏈的FIXaxFX雙專一性抗體

Similar Documents

Publication Publication Date Title
US10723786B2 (en) RSV-specific binding molecule
Milo Therapies for multiple sclerosis targeting B cells
KR102959547B1 (ko) 혈장 칼리크레인 및 인자 xii에 대한 이중특이성 항체
TWI849895B (zh) 雙特異性抗體
KR102171669B1 (ko) 조합물 및 이의 용도
JP2025134874A (ja) ブラジキニンb1受容体リガンドに対する抗体
JP2017507954A5 (cg-RX-API-DMAC7.html)
JP2023548858A5 (cg-RX-API-DMAC7.html)
JP2017536354A5 (cg-RX-API-DMAC7.html)
JP2024520666A5 (cg-RX-API-DMAC7.html)
CN106794244A (zh) 用于降低心血管风险的方法
JP2024531151A5 (cg-RX-API-DMAC7.html)
CN103864932A (zh) 拮抗抑制血管内皮细胞生长因子与其受体结合的单克隆抗体及其编码序列与用途
KR20180008571A (ko) 다발성 골수종(mm)의 치료
CN1311691A (zh) 抗凝剂和人源化抗冯·维勒布兰德氏因子的单克隆抗体
JP2024540226A5 (cg-RX-API-DMAC7.html)
WO2015028888A2 (en) Pharmaceutical compositions to treat viral infection
JP2024511853A5 (cg-RX-API-DMAC7.html)
US20230406942A1 (en) Igf1r antibodies
JP2022544050A5 (cg-RX-API-DMAC7.html)
US20240207277A1 (en) Methods For Treating Drug and Vaccine Induced Immune Thrombocytopenia by Administering Specific Compounds
JP2022534494A5 (cg-RX-API-DMAC7.html)
JP2023531722A5 (cg-RX-API-DMAC7.html)
JP2013542188A (ja) 治療用第viii因子抗体
JP2022527542A5 (cg-RX-API-DMAC7.html)